Rituximab Impairs B Cell Response But Not T Cell Response to COVID‐19 Vaccine in Autoimmune Diseases

Antibody response to the messenger RNA (mRNA) COVID‐19 vaccine has been shown to be diminished in rituximab (RTX)–treated patients. We undertook this study to compare humoral and T cell responses between healthy controls, patients with autoimmune diseases treated with RTX, and those treated with other immunosuppressants, all of whom had been vaccinated with 2 doses of the mRNA COVID‐19 vaccine.

[1]  C. Hirzel,et al.  Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study , 2021, The Lancet Rheumatology.

[2]  P. Kelleher,et al.  Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression , 2021, Annals of the Rheumatic Diseases.

[3]  Mimi Y. Kim,et al.  Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS–CoV‐2 Vaccination , 2021, Arthritis & rheumatology.

[4]  G. Shefer,et al.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.

[5]  P. Dormitzer,et al.  BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.

[6]  D. Jannat-Khah,et al.  Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases , 2021, Annals of the Rheumatic Diseases.

[7]  L. Trupin,et al.  Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2021, Annals of the Rheumatic Diseases.

[8]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[9]  U. Qimron.  Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[10]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[11]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[12]  D. Douek,et al.  High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage , 2008, Mucosal Immunology.